NEW YORK, June 8 (GenomeWeb News) - Cell Signaling Technology will perform a pilot study for AstraZeneca to find biomarkers of target inhibition using its phospho-proteomics technology, the company said yesterday.
Cell Signaling, based in Beverly, Mass., will study compounds provided by AstraZeneca to find cellular protein tyrosine kinase phosphorylation profiles that indicate target inhibition.
The company will employ its Global Phospho-Signature technology, which combines immunoaffinity purification and mass spectrometry.